Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial.
Cooper N, Ghanima W, Vianelli N, Valcárcel D, Yavaşoğlu İ, Melikyan A, Ruiz EY, Haenig J, Somenzi O, Lee J, Clark J, Zhang Y, Zaja F. Cooper N, et al. Among authors: zaja f. Am J Hematol. 2024 Jan;99(1):57-67. doi: 10.1002/ajh.27131. Epub 2023 Nov 28. Am J Hematol. 2024. PMID: 38014779 Clinical Trial.
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia.
Morabito F, Tripepi G, Mauro FR, Laurenti L, Reda G, Moia R, Condoluci A, Vincelli I, Chiarenza A, Vigna E, Martino EA, Bruzzese A, Mezzatesta S, Laureana R, Cutrona G, Di Raimondo F, Fronza G, Zucchetto A, Bomben R, Rossi FM, Olivieri J, Zaja F, Rossi D, Gaidano G, Del Principe MI, Ilariucci F, Del Poeta G, Ferrarini M, Neri A, Gattei V, Gentile M. Morabito F, et al. Among authors: zaja f. Am J Hematol. 2023 Jul;98(7):E157-E160. doi: 10.1002/ajh.26927. Epub 2023 Apr 17. Am J Hematol. 2023. PMID: 37067157 No abstract available.
Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study "Cervax".
Mohamed S, Lucchini E, Sirianni F, Porrazzo M, Ballotta L, Ballerini M, De Sabbata GM, De Bellis E, Cappuccio I, Granzotto M, Toffoletto B, Fortunati I, Russignan A, Florea EE, Torelli L, Zaja F. Mohamed S, et al. Among authors: zaja f. Front Oncol. 2023 Feb 27;13:1133348. doi: 10.3389/fonc.2023.1133348. eCollection 2023. Front Oncol. 2023. PMID: 36923438 Free PMC article.
Evolving trends in epidemiology and natural history of cardiac amyloidosis: 30-year experience from a tertiary referral center for cardiomyopathies.
Porcari A, Allegro V, Saro R, Varrà GG, Pagura L, Rossi M, Lalario A, Longo F, Korcova R, Dal Ferro M, Perkan A, Dore F, Bussani R, De Sabbata GM, Zaja F, Merlo M, Sinagra G. Porcari A, et al. Among authors: zaja f. Front Cardiovasc Med. 2022 Nov 7;9:1026440. doi: 10.3389/fcvm.2022.1026440. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36419501 Free PMC article.
Preventive versus curative photobiomodulation for oral mucositis in patients with multiple myeloma undergoing hematopoietic stem cell transplantation: which approach is more effective?
Rupel K, Cornacchia A, Poiani M, Mohamed S, De Bellis E, Ballerini M, Bogdan Preda TM, Poropat A, Di Lenarda R, Zaja F, Biasotto M, Ottaviani G. Rupel K, et al. Among authors: zaja f. Support Care Cancer. 2024 Mar 5;32(3):208. doi: 10.1007/s00520-024-08414-5. Support Care Cancer. 2024. PMID: 38438625
Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi.
Margiotta-Casaluci G, Bigliardi S, Cocito F, Meli E, Petrucci L, Nicolosi M, Annibali O, Boccomini C, Bozzoli V, Castellino A, Cattina F, Cenfra N, Ciavarella S, Kovalchuk S, Rotondo F, Fama A, Olivieri J, Zaja F. Margiotta-Casaluci G, et al. Among authors: zaja f. Front Oncol. 2023 Mar 10;13:1120967. doi: 10.3389/fonc.2023.1120967. eCollection 2023. Front Oncol. 2023. PMID: 36969038 Free PMC article.
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Ladetto M, et al. Among authors: zaja f. Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. Blood. 2013. PMID: 24085766 Free article. Clinical Trial.
234 results